Literature DB >> 1393416

Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.

R J Ott1, D Tait, M A Flower, J W Babich, R M Lambrecht.   

Abstract

Patients designated to receive 131I-meta-iodobenzylguanadine (mIBG) for the treatment of neural crest tumours have been scanned with 124I-mIBG using the MUP-PET positron camera. Uptake was detected in tumour sites in lung, liver and abdomen. The tomographic images produced have allowed estimates to be made of the concentration of mIBG in both tumour and normal tissue. From these data it is possible to predict the radiation doses that would be achieved using therapy levels (up to 11 GBq) of 131I-mIBG. The levels of tumour uptake are between 0.5 and 2.0 kBq/g indicating that the radiation doses to tumour would be in the range 3 Gy to 7.5 Gy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1393416     DOI: 10.1259/0007-1285-65-777-787

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

1.  131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Francesco Giammarile; Cumali Aktolun; Richard P Baum; Angelika Bischof Delaloye; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Giovanna Pepe; Sven N Reske; Maria R Castellani; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

2.  A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Authors:  Bao Hu; Amy L Vāvere; Kiel D Neumann; Barry L Shulkin; Stephen G DiMagno; Scott E Snyder
Journal:  ACS Chem Neurosci       Date:  2015-09-11       Impact factor: 4.418

3.  Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

Authors:  J S Lewis; M J Welch; L Tang
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

4.  Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system.

Authors:  Rebecca A Gregory; Claire A Hooker; Mike Partridge; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-14       Impact factor: 9.236

5.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 6.  The production of [124I]iodine and [86Y]yttrium.

Authors:  Jochen Schmitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 7.  Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Authors:  Youngho Seo
Journal:  Nucl Med Mol Imaging       Date:  2019-02-18

Review 8.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 9.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 10.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.